Preparation of cryoprecipitate from riboflavin and UV light-treated plasma.

Background And Objectives: The Mirasol® pathogen reduction technology system for plasma is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. This study was undertaken to evaluate the possibility of making pathogen reduced cryoprecipitate from riboflavin and UV light- treated plasma that meets the quality requirements specified by UK and European guidelines for untreated cryoprecipitate.

Materials And Methods: Cryoprecipitate was made from riboflavin and UV light-treated plasma.

Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18°C.

Background: The Mirasol® Pathogen Reduction Technology (PRT) System for plasma combines riboflavin (vitamin B(2)) and UV light energy to reduce pathogens in plasma products. This study evaluated protein quality of apheresis derived plasma products treated with riboflavin and UV light and stored at -18°C for up to 1 year. Comparisons were made to paired, untreated controls after 6 months and 1 year of storage.

Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C.

Background: The Mirasol pathogen reduction technology system for plasma is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. The objective of this study was to evaluate the in vitro protein quality of previously frozen FFP, thawed, Mirasol-treated and refrozen for a final storage period of up to 2 years at -30 °C.

Materials And Methods: All plasma products were held at 4 ± 2 °C, and frozen within 8h after the start of collection.